Items where authors include "Powles, T."

Article

Vasudev, N.S. orcid.org/0000-0001-8470-7481, Ainsworth, G., Brown, S. et al. (24 more authors) (2023) Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM). Journal of Clinical Oncology. ISSN 0732-183X

Vasudev, N.S. orcid.org/0000-0001-8470-7481, Ainsworth, G. orcid.org/0000-0002-9952-8440, Brown, S. orcid.org/0000-0002-7975-7537 et al. (24 more authors) (2023) Standard versus modified ipilimumab, in combination with nivolumab, in advanced renal cell carcinoma: a randomized phase II trial (PRISM). Journal of Clinical Oncology. JCO2300236. ISSN 0732-183X

Brown, J.E. orcid.org/0000-0003-4960-3032, Royle, K.-L., Gregory, W. et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045

Crabb, S.J. orcid.org/0000-0003-3521-9064, Hussain, S. orcid.org/0000-0003-1552-511X, Soulis, E. orcid.org/0000-0001-9022-9295 et al. (18 more authors) (2023) A randomized, double-blind, biomarker-selected, phase II clinical trial of maintenance poly ADP-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma. Journal of Clinical Oncology, 41 (1). pp. 54-64. ISSN 0732-183X

Hussain, S.A. orcid.org/0000-0003-1552-511X, Lester, J.F., Jackson, R. et al. (17 more authors) (2022) Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE) : a double-blind, randomised, phase 2 trial. The Lancet Oncology, 23 (5). pp. 650-658. ISSN 1470-2045

Fulton, B., Jones, R., Powles, T. et al. (8 more authors) (2020) ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials, 21. 344. ISSN 1745-6215

Birtle, A., Johnson, M., Chester, J. et al. (21 more authors) (2020) Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. The Lancet, 395 (10232). pp. 1268-1277. ISSN 0140-6736

Powles, T., Lackner, M.R., Oudard, S. et al. (18 more authors) (2016) Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 34 (14). 1660-U204. ISSN 0732-183X

Powles, T., Brown, J., Larkin, J. et al. (17 more authors) (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology, 27 (5). pp. 880-886. ISSN 0923-7534

Powles, T., Paterson, A., McCloskey, E. orcid.org/0000-0003-0177-8140 et al. (7 more authors) (2006) Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Research, 8 (2). R13. ISSN 1465-5411

Powles, T., Paterson, A., McCloskey, E. et al. (7 more authors) (2006) Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Research, 8 (2). R13. ISSN 1465-5411

Kanis, J. A., McCloskey, E. V., Powles, T. et al. (3 more authors) (1999) A high incidence of vertebral fracture in women with breast cancer. British Journal of Cancer, 79 (7-8). pp. 1179-1181. ISSN 0007-0920